Fixed-Mass Different Volumes Bupivacaine TAP Block After Cesarean
Ultrasound-guided Transversus Abdominis Plane Block After Cesarean Section Using Two Different Bupivacaine Volumes With a Fixed Drug Mass. A Randomized Comparative Trial.
Cesarean section is commonly associated with moderate to severe postoperative pain, which may delay mobilisation, impair breastfeeding, and affect mother-infant bonding. Although opioids, NSAIDs, and neuraxial techniques are commonly used for post-cesarean analgesia, their side effects have encouraged the use of peripheral nerve blocks such as the transversus abdominis plane block.
The TAP block is a fascial plane block that provides analgesia by depositing local anaesthetic between the internal oblique and transversus abdominis muscles. Its efficacy after cesarean section has been demonstrated, particularly when long-acting intrathecal opioids are not used. However, the optimal local anaesthetic volume and dose remain unclear. Since the TAP block depends on adequate spread of local anaesthetic, larger volumes may improve analgesic coverage, but increasing the dose may raise the risk of systemic toxicity.
Therefore, this study investigates whether using the same fixed mass of bupivacaine in two different volumes affects the analgesic efficacy of TAP block after cesarean section, hypothesising that the larger volume may provide better postoperative analgesia.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 4
Kontakter och platser
Studiekontakt
- Namn: Abeer Ahmed, MD
- Telefonnummer: +201005244590
- E-post: abeer_ahmed@kasralainy.edu.eg
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- full-term parturients,
- aged > 18 years
- ASA physical status II
- patients who are scheduled for elective CS with Pfannenstiel incisions under spinal anaesthesia.
Exclusion Criteria:
- Parturients with contraindications to spinal anaesthesia,
- Having a scar or infection at the site of the block
- BMI > 35 Kg/m2,
- on chronic use of pain medications,
- Refusing to participate.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Fixed-mass, high-volume bupivacaine TAP block
Participants will receive a bilateral ultrasound-guided TAP block using 150 mg of plain bupivacaine, diluted to a total volume of 60 mL, injected as 30 mL per side.
|
Ultrasound-guided bilateral transversus abdominis plane block using 150 mg plain bupivacaine after cesarean section.
The same total bupivacaine dose will be administered in two different volumes: 60 mL total volume, 30 mL per side
Ultrasound-guided bilateral transversus abdominis plane block using 150 mg plain bupivacaine after cesarean section.
The same total bupivacaine dose will be administered in two different volumes: 120 mL total volume, 60 mL per side.
|
|
Experimentell: Fixed-mass, low-volume bupivacaine TAP block
Participants will receive a bilateral ultrasound-guided TAP block using 150 mg of plain bupivacaine, diluted to a total volume of 120 mL, injected as 60 mL per side.
|
Ultrasound-guided bilateral transversus abdominis plane block using 150 mg plain bupivacaine after cesarean section.
The same total bupivacaine dose will be administered in two different volumes: 60 mL total volume, 30 mL per side
Ultrasound-guided bilateral transversus abdominis plane block using 150 mg plain bupivacaine after cesarean section.
The same total bupivacaine dose will be administered in two different volumes: 120 mL total volume, 60 mL per side.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
total postoperative morphine consumption
Tidsram: first 24 hours postoperatively
|
first 24 hours postoperatively
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- MD-185-2023
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .